Abstract
The serum and glucocorticoid inducible protein kinase (SGK) family signals downstream of phosphoinositide-3-kinase (PI3K) and is made up of three isoforms: SGK1, 2, and 3. respectively, and their activity is dependent on growth factor activation. Among these SGK families, one such potential target and a less explored enzyme is SGK3. SGK3 regulates a range of basic cellular processes, such as cell proliferation, migration and survival, thus playing an important role in cancer development. These kinase-signaling pathways present both opportunities and challenges for cancer therapy. In this paper, we reviewed the status of SGK3 regulation and its role in normal cell physiology and transformation. In addition, the potential roles of SGK3 signal transduction in breast cancer and prostate cancer are discussed.
Keywords: SGK3, AKT, PI3K, INPP4B, mTOR, breast cancer, prostate cancer.
Current Signal Transduction Therapy
Title:Mechanisms of Activation and Key Roles of SGK3 Under Physiological Conditions and in Prostate and Breast Cancer
Volume: 16 Issue: 2
Author(s): Rajesh Basnet*Buddha Bahadur Basnet
Affiliation:
- Chinese Academy of Sciences, Beijing,China
Keywords: SGK3, AKT, PI3K, INPP4B, mTOR, breast cancer, prostate cancer.
Abstract: The serum and glucocorticoid inducible protein kinase (SGK) family signals downstream of phosphoinositide-3-kinase (PI3K) and is made up of three isoforms: SGK1, 2, and 3. respectively, and their activity is dependent on growth factor activation. Among these SGK families, one such potential target and a less explored enzyme is SGK3. SGK3 regulates a range of basic cellular processes, such as cell proliferation, migration and survival, thus playing an important role in cancer development. These kinase-signaling pathways present both opportunities and challenges for cancer therapy. In this paper, we reviewed the status of SGK3 regulation and its role in normal cell physiology and transformation. In addition, the potential roles of SGK3 signal transduction in breast cancer and prostate cancer are discussed.
Export Options
About this article
Cite this article as:
Basnet Rajesh *, Basnet Bahadur Buddha , Mechanisms of Activation and Key Roles of SGK3 Under Physiological Conditions and in Prostate and Breast Cancer, Current Signal Transduction Therapy 2021; 16 (2) . https://dx.doi.org/10.2174/1574362415666200203122829
DOI https://dx.doi.org/10.2174/1574362415666200203122829 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gastrin-Releasing Peptide Receptor Targeting in Cancer Treatment: Emerging Signaling Networks and Therapeutic Applications
Current Drug Targets Stem Cell Differentiation Stage Factors from Zebrafish Embryo: A Novel Strategy to Modulate the Fate of Normal and Pathological Human (Stem) Cells
Current Pharmaceutical Biotechnology Stem Cell-based Treatment Strategies for Degenerative Diseases of the Retina
Current Stem Cell Research & Therapy Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies
Current Cancer Drug Targets Vitamin D and Cancer Stem Cells in the Gastrointestinal Tract
Current Medicinal Chemistry Understanding Epithelial-Mesenchymal Transition may Reveal Novel Therapeutic Targets for Oral Squamous Cell Carcinoma
Current Cancer Therapy Reviews Current and Future Prospective of a Versatile Moiety: Imidazole
Current Drug Targets The IGF-I/IGF-I Receptor Pathway: Implications in the Pathophysiology of Thyroid Cancer
Current Medicinal Chemistry Identifying Molecular Targets Mediating the Anticancer Activity of Histone Deacetylase Inhibitors: A Work in Progress
Current Cancer Drug Targets Recent Advances in Copper Radiopharmaceuticals
Current Radiopharmaceuticals Failure of Immune Homeostasis - The Consequences of Under and Over Reactivity
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Regulatory Overview of Biosimilars: Current Scenario and Future Opportunities
Applied Clinical Research, Clinical Trials and Regulatory Affairs The Vitamin D Neuroendocrine System as a Target for Novel Neurotropic Drugs
CNS & Neurological Disorders - Drug Targets Structure-Activity Relationship of Nuclear Receptor-Ligand Interactions
Current Topics in Medicinal Chemistry In Vitro Study of UGT Metabolism and Permeability of Orientin and Isoorientin, Two Active flavonoid C-glycosides
Drug Metabolism Letters T Cell Receptor Bias in Humans
Current Immunology Reviews (Discontinued) Clinical Trials with Oncolytic Adenovirus in China
Current Cancer Drug Targets Nitric Oxide and Pancreatic Cancer Pathogenesis, Prevention, and Treatment
Current Pharmaceutical Design Anti-Cytokine Therapeutics: History and Update
Current Pharmaceutical Design